Secukinumab effectively manages ankylosing spondylitis in a hemodialysis patient without side effects

Ankylosing spondylitis (AS) is a chronic, progressive inflammatory disease that primarily affects the spine and sacroiliac joints. In recent years, biologic agents have gained increasing popularity in the treatment of AS due to their high targeting specificity and favorable side effect profiles. Among these, secukinumab has emerged as an effective treatment option. However, the safety and efficacy of secukinumab in patients undergoing hemodialysis has not yet been thoroughly verified.

Here, we report the successful treatment of AS with secukinumab in a 36-year-old male patient undergoing hemodialysis. The patient presented with recurrent lumbosacral pain and tested positive for HLA-B27. After treatment, significant improvements were observed in both the imaging characteristics of the synovial joints and the patient's symptoms.

This case suggests that secukinumab may have a positive effect on AS in patients on hemodialysis, without apparent adverse effects.